Schering Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

Jan Huebner

Rolf Bohlmann

Joachim Kuhnke

Orlin Petrov

Frederik Menges

Hans-Peter Muhn

Katja Prelle

Steffen Borden

Johannes Platzek

Werner Skuballa

Ulrich Klar

Hartmut Rehwinkel

Thomas Frenzel

Norbert Schmees

Sven Ring

Stefan Jaroch

Heike Schaecke

Christian Dinter

Matthias Schneider

Norbert Gallus

The 17&#x3b2;-cyano-19-nor-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSOR, in which R is hydrogen or C-C-alkyl, Ris hydrogen or halogen, furthermore either: R, Rtogether form methylene or 1,2-ethanediyl or Ris hydrogen and Ris selected from the group comprising hydrogen, methyl and hydroxymethylene, and Ris selected from the group comprising hydrogen, C-C-alkyl, C-C-alkenyl and cyclopropyl, or: Ris hydrogen and Rand Rtogether form methylene or are omitted with formation of a double bond between Cand C, R, Rare hydrogen or are omitted with formation of a double bond between Cand C, R, Rare hydrogen or together form methylene, Ris selected from the group comprising hydrogen, C-C-alkyl and allyl, where at least one of the substituents R, R, R, R, R, Rand Ris unequal to hydrogen or Rand Rare omitted with formation of a double bond between Cand C, and moreover comprise their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts. 

17&#x3b2;-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative

The present invention describes the novel 18-methyl-19-norandrost-4-ene 17,17-spiro ethers of the general formula I in which The novel compounds have progestational and antimineralocorticoid activity.

18-Methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same

Compounds of general formula (IIa) or (IIb) and their use as pharmaceutical agents.

5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents

A new process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride is described.

Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride

Growing community of inventors

Berlin, Germany

Jan Huebner